KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $55.3 million.

  • Castle Biosciences' Total Current Liabilities rose 2486.29% to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year increase of 2486.29%. This contributed to the annual value of $49.4 million for FY2024, which is 361.89% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Total Current Liabilities is $55.3 million, which was up 2486.29% from $50.9 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Total Current Liabilities registered a high of $55.3 million during Q3 2025, and its lowest value of $17.6 million during Q1 2021.
  • Its 5-year average for Total Current Liabilities is $35.5 million, with a median of $36.1 million in 2022.
  • In the last 5 years, Castle Biosciences' Total Current Liabilities plummeted by 3394.94% in 2021 and then skyrocketed by 12483.22% in 2022.
  • Over the past 5 years, Castle Biosciences' Total Current Liabilities (Quarter) stood at $24.9 million in 2021, then surged by 45.17% to $36.1 million in 2022, then skyrocketed by 31.94% to $47.7 million in 2023, then increased by 3.62% to $49.4 million in 2024, then grew by 11.98% to $55.3 million in 2025.
  • Its Total Current Liabilities stands at $55.3 million for Q3 2025, versus $50.9 million for Q2 2025 and $37.3 million for Q1 2025.